← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Bristol Myers Squibb returned to profit and kept producing major free cash flow, but revenue was flat and the portfolio still faces patent, pricing, and replacement-cycle pressure.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -0.2% to $48.19BNote
- Profitability — Net income +178.8% to $7.05BOK
- Cash quality — FCF -7.9% to $12.85BWatch
- Margins — Net margin +3317 bpsOK
- Capital — Debt -9.3%; dividends +3.7%OK
- Insiders — 0 open-market buys / 3 sellsWatch
Business
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular, neuroscience, and other serious diseases, with a single operating segment built around discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines.
Where the revenue comes from
Fiscal 2025, as BRISTOL MYERS SQUIBB CO reports it. History and quarterly detail are in the app.
- Gross product sales$88.1B
- Net product sales$46.8B
- Growth Portfolio$26.4B
- Legacy Portfolio$21.8B
- Alliance and other revenues$1.4B
Leadership changes
From BRISTOL MYERS SQUIBB CO's own filings, the day they're filed.
- Samit Hirawat · Chief Medical Officer · departureeff. 2025-08-01
- Phil Holzer · President · appointmenteff. 2024-02-15
- Sharon Greenlees · President · appointmenteff. 2024-02-15
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-05-08
- 8-K · Company announcement2026-04-30
- 10-Q · Quarterly report2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BRISTOL MYERS SQUIBB CO, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.